iShares Genomics Immunology and Healthcare ETF (IDNA) |
| 40.2 0.53 (1.34%) 09-02 16:00 |
| Open: | 40.475 |
| High: | 40.6199 |
| Low: | 39.6571 |
| Volume: | 142,277 |
| Market Cap: | 188(M) |
| PE Ratio: | 25.83 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 48.46 |
| Resistance 1: | 41.49 |
| Pivot price: | 38.88 |
| Support 1: | 35.49 |
| Support 2: | 31.78 |
| 52w High: | 41.49 |
| 52w Low: | 22.313 |
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to mirror the investment performance of a specific index. This index comprises companies operating in both mature and emerging global markets. These businesses are strategically chosen for their potential to capitalize on sustained innovation and expansion within the crucial fields of genomics, immunology, and bioengineering.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 01 Sep 2026
The Next Biotech Boom May Be Cancer Vaccines. Watch These ETFs - Moderna (NASDAQ:MRNA) - Benzinga
Tue, 01 Sep 2026
Why (IDNA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Wed, 19 Aug 2026
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK) - Benzinga
Wed, 19 Aug 2026
Healthcare ETFs rally as Moderna nearly doubles on melanoma win - Seeking Alpha
Wed, 12 Aug 2026
5 Best CRISPR Gene Editing ETFs for 2026 and How to Invest - The Motley Fool
Tue, 23 Jun 2026
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead? - TradingView
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
